Nima Farzan
CIK: 0001808296
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)1 (33.3%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (66.7%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
About Farzan Nima
Farzan Nima (SEC CIK 0001808296) files insider reports with the SEC as President and CEO of Latigo Biotherapeutics, Inc. (LTGO) and Director of Keros Therapeutics, Inc. (KROS).
Signal8 holds 4 ownership filings by Farzan Nima (1 Form 3, 3 Form 4), filed between Jun 6, 2025 and Aug 6, 2026. Those filings report 3 transactions, from Jun 4, 2025 to Jun 4, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Farzan Nima's filings is in LEXINGTON, MA.
Recent filings by Farzan Nima
Other insiders filing for Latigo Biotherapeutics, Inc. (LTGO)
- 5AM Ventures VI, L.P., 10% Owner
- Sanofi, 10% Owner
- Westlake BioPartners Fund I, L.P., 10% Owner
- Foresite Capital Management V, LLC, 10% Owner
- SMITH TODD N, Director
- Tananbaum James B., Director